New hope for advanced breast cancer: drug combo trial launches

NCT ID NCT07558733

Recruiting now Disease control Sponsor: Faeth Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests two experimental drugs, sapanisertib and serabelisib, combined with standard therapy for people with HR+/HER2- advanced or metastatic breast cancer. The goal is to find safe doses and see if the combination can shrink tumors or slow the disease. About 32 adults who have already tried at least one prior treatment will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HR+/HER2- BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm hereditary sensory and autonomic neuropathy hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HR+/HER2- BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Oncology Associates of Oregon
RECRUITING

Springfield, Oregon, 97477, United States
Rocky Mountain Cancer Centers
RECRUITING

Lone Tree, Colorado, 80124, United States
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
START Los Angeles
RECRUITING

Los Angeles, California, 90025, United States
START San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Texas Oncology - Central/South
RECRUITING

Austin, Texas, 78731, United States
Texas Oncology - San Aantonio
RECRUITING

San Antonio, Texas, 78240, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.